| CASE REPORT |
|
| Year : 2018 | Volume
: 10
| Issue : 2 | Page : 89-91 |
|
|
Nilotinib-induced perforating folliculitis: Two cases
Neerja Saraswat1, Ajay Chopra1, Debdeep Mitra1, Krishna Talukdar2
1 Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
2 Department of Dermatology, Jorhat Medical College and Hospital, Jorhat, Assam, India
Correspondence Address:
Dr. Debdeep Mitra
Department of Dermatology, Base Hospital Delhi Cantt, New Delhi - 110 010
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_85_17
|
|
|
Cutaneous adverse effects of chemotherapy are widely known but underreported. A significant advancement is made in the field of oncology with the advent of new classes of drug being added to the existing classes at a fast pace. Most of these cutaneous adverse effects are self-limiting and subsides on suspending the drug either temporarily or permanently. Some of these effects are merely overlooked by the patients and the treating physician hence goes un-noticed. Nilotinib is a newer second-generation tyrosine-kinase inhibitor approved for the management of chronic myeloid leukemia. This drug is rapidly establishing itself as a first-line therapy for chronic myeloid leukemia. Like other chemotherapeutic agents, a wide array of cutaneous adverse effects is noted with this drug. We report two cases of perforating folliculitis induced by nilotinib. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
